Use cautionDrug recall · FDA · Published November 25, 2020
US Compounding Recalls Neostigmine Syringes Due to Missing Label
US Compounding Inc recalls 1,640 syringes of Neostigmine Methylsulfate because labels are missing. Check lot numbers and contact the company for details.
📍Recalling firmUS Compounding Inc1270 Dons Ln · Conway, AR 72032-4753
✎ GovInfoNow plain-language explainer
US Compounding Inc is recalling Neostigmine Methylsulfate PF Inj. 5 mg/5 mL single-use syringes because the product labels are missing. This issue affects 1,640 syringes distributed nationwide. The record does not specify a remedy or return process for this recall. Read more at govinfonow.com/recall/36650-us-compounding-recalls-neostigmine-syringes-due-to-missing-label.
“US Compounding Recalls Neostigmine Syringes Due to Missing Label.” GovInfoNow, updated October 11, 2026. https://govinfonow.com/recall/36650-us-compounding-recalls-neostigmine-syringes-due-to-missing-label. Based on FDA recall #D-0175-2021 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0175-2021%22&limit=1).
The Food and Drug Administration announced on Nov. 25, 2020, that US Compounding Inc recalled Neostigmine Methylsulfate Injections due to missing labels. The agency issued the recall for Class III products distributed nationwide.
How to tell if you have it
Brand: US Compounding
Product: Neostigmine Methylsulfate Injections
Description: Neostigmine Methylsulfate PF Inj. 5 mg/5 mL, 5 mL Single Use Syringes, Hospital/Office Use Only
NDC: 62295-3324-05
Lot: 20202109@3
BUD: 3/20/2021
Quantity: 1640 syringes
The hazard
The recall involves Neostigmine Methylsulfate PF Inj. 5 mg/5 mL, 5 mL Single Use Syringes where the label is missing. The FDA classified this as a Class III recall.
Context
GovInfoNow's records show US Compounding Inc has had six other recalls since May 16, 2014. On Dec. 16, 2020, the company recalled syringes with illegible lot and expiry dates. Other recent recalls of similar products include American Regent Levocarnitine Injection Recall: Missing Label Hazard (April 16, 2026) and Shoolin Pharma Chem Tadalafil Recall: FDA Inspection Findings (Aug. 3, 2026).
How to tell if you have this one
Look for Neostigmine Methylsulfate PF Inj. 5 mg/5 mL in 5 mL single-use syringes manufactured by US Compounding Inc. Check for NDC 62295-3324-05 and Lot number 20202109@3 with a BUD of 3/20/2021.
Brand
US Compounding
Category
Drug
Based on the official FDA remedy
What to do — step by step
Identify Affected Syringes
Check your inventory for Neostigmine Methylsulfate PF Inj. 5 mg/5 mL syringes with NDC 62295-3324-05 and Lot 20202109@3.
Contact Manufacturer
Call US Compounding Inc at (800) 718-3588 for further instructions regarding the missing label issue.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 11 months after the firm started it.
1Firm started the recall
2FDA classified it Class III
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0175-2021 (November 25, 2020) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0175-2021 to see it in context.
Plain-language summary written by qwen3.6:35b-a3b on October 11, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.